In an insightful interview with ETPharma’s Rashmi Mbian Kaur, Dr. Ashish GawdeCountry Medical Director, Pharmaceuticals, South Asia, BayerDiscusses significant challenges faced by patients with retinal diseases, including financial burden, geographic disparity, and lack of awareness. Dr. Gawade emphasizes the transformative role of technology, from AI to telemedicine, in revolutionizing the diagnosis and management of eye diseases. Edited excerpts below:
Q. In your experience, what are the biggest challenges patients with retinal diseases face in getting eye care?
The most pressing challenges include the financial and emotional burdens associated with frequent, long-term treatment for conditions such as diabetic macular edema (DME) and wet age-related macular degeneration (AMD). These treatments often require long-term maintenance, and this can affect adherence, as patients may prioritize immediate concerns over routine care. Access to timely and effective treatment for retinal diseases is a significant barrier for many patients.
In addition, geographic disparities may affect access to treatment. Individuals in rural or underserved areas may need to travel long distances to access specialty care, which can affect adherence and lead to delays in treatment. Additionally, lack of awareness of retinal diseases contributes to late diagnosis, with many individuals seeking treatment only after significant vision loss. This highlights the urgent need for widespread education on early warning signs and the importance of regular eye examinations.
To address these challenges, Bayer has implemented innovative patient assistance initiatives such as the “Eylea 4 U” program, which ensures timely access to treatment. Collaborations with organizations like Health Finance enhance our ability to effectively reach patients, ensuring they receive the care they need for optimal outcomes.
Q. How has EYLEA changed the treatment landscape for patients with retinal diseases?
The launch of Eylea (aflibercept solution) has brought about a major change in the management of retinal diseases such as wet AMD and DME. Eylea is clinically proven to be superior in efficacy to other treatment options available for retinal diseases. Now, with a new dosage regimen, Eylea offers the same effectiveness but with fewer injections. Dosing regimens can be individualized based on the unique needs of each patient. These advances not only improve patient compliance but also overall quality of life, allowing individuals to maintain greater independence in their daily activities. Eylea’s development reflects a broader movement toward personalized treatment strategies. This personalized approach ensures optimal care and reduces the burden associated with frequent injections in previous treatment regimens.
Q. How do you envision the role of evolving technology in the treatment and management of eye diseases?
The future of ophthalmology is being redefined by the rapid convergence of technologies, presenting exciting prospects for the diagnosis and management of eye diseases. Innovations such as artificial intelligence (AI) are revolutionizing diagnostic accuracy, enabling healthcare providers to detect conditions such as diabetic retinopathy and AMD at earlier stages. These technological advances ensure that patients receive timely intervention, ultimately preserving vision.
Telemedicine also plays a transformative role, allowing patients in remote areas to access specialized care without the logistical challenges of travel. This increased accessibility is crucial for populations that may otherwise delay needed treatment.
Q. How is Bayer working to make eye disease treatment options more accessible in India?
We are committed to increasing the accessibility of treatment for eye diseases across India, especially in areas where specialized care is less available. We support patients with initiatives such as the Eylea Easy Pay program, offering flexible and affordable payment options to improve access to Eylea (aflibercept solution) in India. Such initiatives provide managed payment solutions for patients undergoing treatment for retinal diseases, reduce the logistical burden associated with ongoing care, and promote adherence to treatment regimens.
In addition to financial assistance programs, Bayer has established outreach initiatives that emphasize the importance of regular eye exams and early intervention. By engaging with communities, we aim to educate patients about the risks associated with untreated retinal diseases and empower them to seek timely care.
Q. How do you see the future of ophthalmology and treatment in eye care?
The future of ophthalmology is on the brink of significant advances, driven by continued innovation in treatment and preventive care strategies. There is a palpable sense of optimism surrounding the development of new therapies, including gene therapy, which promise to provide solutions for genetic retinal disorders. As research progresses, advances are expected to address conditions previously thought to be untreatable, significantly increasing the quality of life for countless patients.
Additionally, the integration of technology – particularly artificial intelligence and telehealth solutions – will improve diagnostic accuracy and expand access to care. With increasing emphasis on preventive measures, the goal is to reduce the incidence of vision loss due to conditions such as wet AMD and DME through early detection and timely intervention.
We are committed to playing a key role in this evolving landscape by investing in the research and development of innovative therapies and forging partnerships that advance eye care. Our highest ambition is to build a future where preventable blindness is significantly reduced and everyone has access to the comprehensive eye care they deserve.
